Nomograms for Prediction of Disease Recurrence in Patients with Primary Ta, T1 Transitional Cell Carcinoma of the Bladder

We developed nomograms to predict disease recurrence in patients with Ta, T1 transitional cell carcinoma of the bladder. Thirty-eight training hospitals participated in this retrospective multicenter study. Between 1998 and 2002, a total of 1,587 patients with newly diagnosed non-muscle invasive bladder cancer were enrolled in this study. Patients with prior histories of bladder cancer, non-transitional cell carcinoma, or a follow-up duration of less than 12 months were excluded. With univariate and multivariate logistic regression analyses, we constructed nomograms to predict disease recurrence, and internal validation was performed using statistical techniques. Three-year and five-year recurrence-free rates were 64.3% and 55.3%, respectively. Multivariate analysis revealed that age (hazard ratio [HR]=1.437, p<0.001), tumor size (HR=1.328, p=0.001), multiplicity (HR=1.505, p<0.001), tumor grade (HR=1.347, p=0.007), concomitant carcinoma in situ (HR=1.611, p=0.007), and intravesical therapy (HR=0.681, p<0.001) were independent predictors for disease recurrence. Based on these prognostic factors, nomograms for the prediction of disease recurrence were developed. These nomograms can be used to predict the probability of disease recurrence in patients with newly diagnosed Ta, T1 transitional cell carcinoma of the bladder. They may be useful for patient counseling, clinical trial design, and patient follow-up planning

Relationship between Onodera׳s Prognostic Nutritional Index and Subpopulation Lymphocyte Counts in Hemodialysis and Peritoneal Dialysis Patients

No standard method for assessing the nutritional status in dialysis patients. In the present study, we undertook an evaluation to determine whether estimation of geriatric nutritional risk index (GNRI) and lymphocyte subset counts can be helpful in diagnosis of malnutrition in hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients. Methods: We examined the GNRI and lymphocyte subset counts of 50 HD patients (55.8±12.7 years; 28 men and 22 women) and 16 CAPD patients (49.8±14.5 years; 10 men and 6 women). The GNRI is calculated based on the serum albumin level and total lymphocyte count and uses the following equation: GNRI=[14.89×albumin (g/dL)]+ [41.7×(weight/ideal body weight)]. Logistic regression analysis was performed for predicting malnutrition in dialysis patients. Results: The average GNRI value was 100.1±8.4 in HD patients and 99.2±8.1, and GNRI values were normally distributed. lymphocyte subset counts were not different between HD patients and CAPD patients. Lymphocyte subset counts were lower in patients with higher GNRI (GNRI ≥100). According to logistic regression for predicting malnutrition according to GNRI, age, female and CD 19 count predicted malnutrition in hemodialysis and peritoneal dialysis patients Conclusions: These results suggest that GNRI and lymphocyte subset counts (especially CD 19 count) may be a significant nutritional marker in HD and CAPD patients

A back-to-back tumor composed of papillary renal cell carcinoma and oncocytoma treated by laparoscopic partial nephrectomy: a case report

Abstract Background Renal oncocytoma is the most common benign renal tumor, and papillary renal cell carcinoma is the second most common histologic subtype of renal cell carcinoma. Renal tumors containing different components such as papillary renal cell carcinoma and oncocytoma are extremely rare. Case presentation A renal mass was incidentally detected in a 52-year-old Korean woman, and a computed tomographic scan showed a 32-mm multicystic mass with some calcifications in the lower pole of the right kidney. She underwent laparoscopic partial nephrectomy without any perioperative complications. We found a papillary renal cell carcinoma and an oncocytoma in a tumor mass. Conclusions The possibility of a mixed malignant tumor should be considered while treating benign tumors such as oncocytoma